melanoma

melanoma
Name	Melanoma
Field	Dermatology, Oncology

melanoma is a malignant neoplasm originating from melanocytes in the skin, mucosa, eye, or meninges, notable for aggressive local invasion and early metastasis. It is a major focus of clinical practice in Dermatology, Oncology, Ophthalmology, Pathology, and public health programs led by organizations such as the World Health Organization and the Centers for Disease Control and Prevention. Research into its molecular drivers intersects with institutions like the National Cancer Institute and academic centers including Dana-Farber Cancer Institute and Memorial Sloan Kettering Cancer Center.

Signs and symptoms

Early lesions often present as asymmetric pigmented macules or papules with irregular borders and color variegation; advanced disease may produce nodules, ulceration, bleeding, and satellite lesions. Patients commonly note changes in size, shape, color, or sensation of a nevus; clinicians in Royal College of Physicians-affiliated clinics and emergency departments evaluate such lesions alongside dermatologists from centers like Mayo Clinic and Cleveland Clinic. Mucosal melanomas may manifest with bleeding or obstruction in sites managed by specialists at institutions such as Johns Hopkins Hospital. Ocular melanoma can present with visual disturbance and is assessed by teams associated with Bascom Palmer Eye Institute and Wills Eye Hospital.

Causes and risk factors

Ultraviolet radiation exposure—particularly intermittent, intense exposure and sunburns—is a principal environmental risk identified in epidemiologic studies from agencies like the International Agency for Research on Cancer; other risks include ionizing radiation exposure in settings overseen by United Nations Scientific Committee on the Effects of Atomic Radiation-related research. Host factors include fair phototype, numerous or atypical nevi, family history linked to genes studied at the Broad Institute and Wellcome Sanger Institute such as CDKN2A and BRAF variants. Immunosuppression associated with organ transplantation programs at centers like Cleveland Clinic and HIV infection monitored by UNAIDS increases incidence. Geographic and occupational patterns noted in reports from the European Commission and national cancer registries contribute to risk stratification.

Pathophysiology and subtypes

Melanomagenesis involves dysregulated signaling through pathways characterized by mutations in genes including BRAF, NRAS, KIT, and loss of tumor suppressors (CDKN2A, PTEN); these molecular alterations have been characterized in genomic projects at the Cancer Genome Atlas and by labs at Sanger Institute. Histologic subtypes include superficial spreading, nodular, lentigo maligna, acral lentiginous, mucosal, and uveal forms—each with distinct anatomic predilections and biological behavior described in textbooks from publishers like Elsevier and Springer. Tumor microenvironment interactions with immune checkpoints (PD-1/PD-L1, CTLA-4) underpin therapeutic strategies developed by pharmaceutical companies such as Merck & Co. and Bristol Myers Squibb and evaluated in trials organized by groups like the European Organisation for Research and Treatment of Cancer.

Diagnosis

Clinical inspection using dermoscopy, excisional biopsy with histopathology assessed by pathologists trained in standards promulgated by the College of American Pathologists, and ancillary molecular testing performed in laboratories accredited by bodies like Clinical Laboratory Improvement Amendments are cornerstones of diagnosis. Imaging for metastatic evaluation includes PET-CT and MRI modalities produced by companies such as GE Healthcare and Siemens Healthineers, guided by staging systems from the American Joint Committee on Cancer. Multidisciplinary tumor boards at comprehensive cancer centers coordinate diagnostic workflows.

Staging and prognosis

Staging follows the TNM framework in the American Joint Committee on Cancer staging manual, incorporating Breslow thickness, ulceration, nodal involvement, and distant metastases; prognosis is determined by these parameters and molecular features identified by research consortia like the International Melanoma Research Group. Survival statistics reported by national registries such as Surveillance, Epidemiology, and End Results Program inform prognostic counseling. Sentinel lymph node biopsy techniques developed by surgical teams influenced by work at Johns Hopkins Hospital refine staging accuracy.

Prevention and screening

Primary prevention emphasizes ultraviolet avoidance, sunscreen use, and behavioral interventions promoted by public health campaigns run by World Health Organization, American Cancer Society, and national health services (e.g., National Health Service (England)). Secondary prevention includes skin self-examination and professional surveillance programs implemented in dermatology clinics affiliated with institutions like St. John’s Institute of Dermatology. Occupational and travel guidelines by bodies such as the International Labour Organization and Centers for Disease Control and Prevention address high-exposure populations. Screening policies vary between countries and are informed by cost-effectiveness analyses from agencies like the National Institute for Health and Care Excellence.

Treatment

Localized disease is managed with surgical excision per guidelines from societies including the European Society for Medical Oncology and the National Comprehensive Cancer Network; advanced disease treatment includes immune checkpoint inhibitors (e.g., anti-PD-1, anti-CTLA-4) and targeted therapies for BRAF-mutant tumors developed by companies such as Roche and Novartis and tested in clinical trials run by cooperative groups like SWOG. Adjuvant therapy, regional therapies (isolated limb perfusion), radiotherapy, and palliative interventions are coordinated within multidisciplinary oncology services at comprehensive centers including MD Anderson Cancer Center.

Epidemiology and public health impact

Incidence varies globally, with highest rates reported in populations monitored by registries in Australia, New Zealand, United States, and parts of Europe, reflecting interactions of phenotype, sun exposure, and screening practices studied by the International Agency for Research on Cancer. Mortality trends and burden of disease analyses published by World Health Organization and country-level health departments guide prevention funding and research priorities supported by organizations like the American Cancer Society and philanthropic funders such as the Melanoma Research Alliance.

Category:Skin cancer